Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brieva

Showing results (271-280 of 376) with videos related to

Pageof 38
Sort By:
British Journal of Haematology|October 3, 2002
CD106 and activated-CD29 are expressed on myelomatous bone marrow plasma cells and their downregulation is associated with tumour progressionRosario Luque, José Antonio García-Trujillo, Carmen Cámara, et al.
Pharmaceuticals (Basel, Switzerland)|April 27, 2024
Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?Anna Gil-Sánchez, Hugo Gonzalo, Marc Canudes, et al.
Journal of Drugs in Dermatology : JDD|January 10, 2022
Alteration to the Skin Ceramide Profile Following Broad-Spectrum UV ExposureRebecca Barresi, Hawasatu Dumbuya, I-Chien Liao, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 23, 2009
The search for responsive clinical endpoints in primary progressive multiple sclerosisL V A E Bosma, J J Kragt, L Brieva, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 22, 2010
Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?L V A E Bosma, J J Kragt, L Brieva, et al.
Molecular Neurobiology|June 17, 2026
18:2 Cholesterol Ester is a Novel Prognostic Biomarker of Disease Progression in Multiple SclerosisPascual Torres, Anna Gil Sánchez, Agustín Sancho-Saldaña, et al.
Seminars in Oncology|December 18, 2020
A double-edged sword: Prolonged detection of SARS-COV-2 in patients receiving cancer directed therapyWinston Wong, Claire Brieva, Michael May, et al.
Neurodegenerative Disease Management|May 10, 2021
Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapiesJosé Meca-Lallana, Juan Antonio García-Merino, Sergio Martínez-Yélamos, et al.
International Immunopharmacology|May 26, 2005
AM3 inhibits LPS-induced iNOS expression in micePedro Majano, José Luis Alonso-Lebrero, Agnieszka Janczyk, et al.
Medicina Clinica|February 10, 1996
[Immunologic reconstitution of peripheral blood lymphocytes in patients treated by bone marrow transplantation]C Parra, E Roldán, C Rodríguez, et al.
Pageof 38

Showing results (271-280 of 376) with videos related to

Sort By:
Pageof 38
British Journal of Haematology|October 3, 2002
CD106 and activated-CD29 are expressed on myelomatous bone marrow plasma cells and their downregulation is associated with tumour progressionRosario Luque, José Antonio García-Trujillo, Carmen Cámara, et al.
Pharmaceuticals (Basel, Switzerland)|April 27, 2024
Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?Anna Gil-Sánchez, Hugo Gonzalo, Marc Canudes, et al.
Journal of Drugs in Dermatology : JDD|January 10, 2022
Alteration to the Skin Ceramide Profile Following Broad-Spectrum UV ExposureRebecca Barresi, Hawasatu Dumbuya, I-Chien Liao, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 23, 2009
The search for responsive clinical endpoints in primary progressive multiple sclerosisL V A E Bosma, J J Kragt, L Brieva, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 22, 2010
Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?L V A E Bosma, J J Kragt, L Brieva, et al.
Molecular Neurobiology|June 17, 2026
18:2 Cholesterol Ester is a Novel Prognostic Biomarker of Disease Progression in Multiple SclerosisPascual Torres, Anna Gil Sánchez, Agustín Sancho-Saldaña, et al.
Seminars in Oncology|December 18, 2020
A double-edged sword: Prolonged detection of SARS-COV-2 in patients receiving cancer directed therapyWinston Wong, Claire Brieva, Michael May, et al.
Neurodegenerative Disease Management|May 10, 2021
Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapiesJosé Meca-Lallana, Juan Antonio García-Merino, Sergio Martínez-Yélamos, et al.
International Immunopharmacology|May 26, 2005
AM3 inhibits LPS-induced iNOS expression in micePedro Majano, José Luis Alonso-Lebrero, Agnieszka Janczyk, et al.
Medicina Clinica|February 10, 1996
[Immunologic reconstitution of peripheral blood lymphocytes in patients treated by bone marrow transplantation]C Parra, E Roldán, C Rodríguez, et al.
Pageof 38